Patients will undergo leukapheresis.

Leukapheresis will be performed on the following day.

A HLA-A2 positive healthy donor undergoes leukapheresis.

CD8 T cells are purified using MACS cell separation.

PBMC are isolated from buffy coats by density gradient centrifugation using Biocoll (BIOCHROM).

Patients receive V administrations with eventual additional ones depending on clinical outcome.

Day 4: harvesting (virus-containing)

DCs are washed.

refolded CD1 molecules are used to generate CD1 tetramers

The DC vaccine will consist of monocyte derived DC loaded with tumor lysate generated from the excised lesion.

Such prepared DC will be used also to expand T cells (isolated during the elutriation) for subsequent adoptive transfer.

The DC with blocking receptors are exposed to fungi.

Sources for tumor antigens as well as monocytes and T cells will be isolated from the leukapheresis product by elutriation.

Dendritic cells are electroporated.

Electroporation of autologous DCs electroporated with mRNA encoding CD40L, CD70, caTLR4 and one tumorantigen (gp100, Tyrosinase, Mage-C2 or Mage-A3) to produce the vaccine

Elutriation of the leukapheresis product.

Leukapheresis products from cancer patients is used as a starting material for monocyte enrichment by elutriation technology with ELUTRA® (Gambro).

Blue formazan particles are dissolved using 2M KOH and DMSO.

After peptide pulsation cells are diluted in medium containing 20 ng/mL TNF-?, plus IL-4 and GM-CSF as stated above.